Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development.
The European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previously received at least 2 treatment regimens.
Waldenstrom's Macroglobulinemia Clinical Trial Pipeline Insights | 20+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.